Metastatic Hormone Refractory Prostate Cancer Recruiting Phase 2 / 3 Trials for Enzalutamide (DB08899)

Also known as: Metastatic hormone refractory Prostate cancer / Metastatic Prostate cancer / Prostate cancer metastatic / Metastatic Prostate Carcinoma / Carcinoma of the prostate metastatic / Prostatic cancer metastatic

DBCOND0036371 (Metastatic Hormone Refractory Prostate Cancer)Recruiting2 / 3 IdentifierTitlePurposeDrugs
NCT03295565Optimal Sequencing of Treatment Options for Poor Risk mCRPC Previously Treated With DocetaxelTreatment